CRESCENT BIOPHARMA, INC. (CBIO) Return on equity 2016–2025
CRESCENT BIOPHARMA, INC. (CBIO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-75.8%FY2025 · since FY2016: -90.1% → -75.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -75.8% | — |
| FY2023 | -96.1% | +12.7 pp |
| FY2022 | -108.8% | -31.0 pp |
| FY2021 | -77.7% | -37.9 pp |
| FY2020 | -39.8% | — |
| FY2016 | -90.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CBIO financial trends
CBIO RevenueCBIO Net incomeCBIO Net marginCBIO Gross profitCBIO Gross marginCBIO Operating incomeCBIO Operating marginCBIO Operating cash flowCBIO Free cash flowCBIO Capital expendituresCBIO Stock buybacksCBIO Dividends paidCBIO Total assetsCBIO Total liabilitiesCBIO Shareholders’ equityCBIO overview →